Abiraterone - USA

IPR decision (January 17, 2018):

AIA Review	Filing Date	Institution Date	Petitioner	Patent No.	Status
IPR2016-01317 IPR2016-00286 IPR2016-01582 IPR2017-00853 IPR2016-01332	12/04/2015 06/29/2016 06/30/2016 08/10/2016 02/08/2017	05/31/2016 09/19/2016 01/10/2017 01/19/2017 04/12/2017	Amerigen Argentum Mylan Wockhardt Actavis	US 8,822,438	Final Written Decision (claims 1–20 are unpatentable)

PTAB concluded that Petitioner has demonstrated that the preponderance of the evidence of record supports that it would have been obvious to the ordinary artisan at the time of invention to combine Gerber with O’Donnell or Barrie and/or Sartor, with a reasonable expectation of success. The secondary considerations of nonobviousness raised by Patent Owner are neutral or not in favor of the patentability of the challenged claims, and do not outweigh the other Graham factors in obviousness analysis.

US 8,822,438 (expiring on Aug 24, 2027) claims a method for the treatment of a prostate cancer with abiraterone and prednisone.